Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Under the transaction, Mylan N.V., a new Dutch top holding company, will acquire these assets in exchange for approximately 21% of the shares in the new combined company Mylan N.V. with an approximate value of $5.3 billion, and Mylan Inc. will become a subsidiary of Mylan N.V. by means of a U.S. merger, resulting in the current Mylan shareholders owning approximately 79% of Mylan N.V. Mylan N.V. will be listed on the NASDAQ. The transaction is expected to complete in the first quarter of 2015 and is subject to closing conditions such as competition approvals and approval by Mylan Inc.’s shareholders.
